Product Images Finasteride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Finasteride NDC 68071-1648 by Nucare Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

68071 1648 9

68071 1648 9

NuCare Pharmaceuticals is a company that produces a medication called Finasteride 5mg in the form of 90 tablets. The medication is used for a specific purpose, but that information is not available in the provided text. The manufacturer's NDC (National Drug Code) for this product is 31722-525-50. The expiration date is not readable in the text. It is important to consult a doctor for medication advice and information on potential side effects. The text also includes a warning to keep the medication out of reach of children and store it at a controlled temperature of 68.77°F.*

Figure 1 Symptom Score in a Long-Term Efficacy and Safety Study - finasteride fig1

Figure 1 Symptom Score in a Long-Term Efficacy and Safety Study - finasteride fig1

Figure 2 Percent of Patients Having Surgery for BPH, Including TURP - finasteride fig2

Figure 2 Percent of Patients Having Surgery for BPH, Including TURP - finasteride fig2

Figure 4 Prostate Volume in a Long-Term Efficacy and Safety Study - finasteride fig3

Figure 4 Prostate Volume in a Long-Term Efficacy and Safety Study - finasteride fig3

Mean Percent Change from Baseline + 1 SE in Prostate Volume in a Long-Term Efficacy and Safety Study. The study compares the baseline prostate volume with the prostate volume at Year 1, Year 2, Year 3, and Year 4 for two groups: Placebo and Finasteride. The numbers indicate the average change from baseline and 1 standard error (SE) for each year. The Placebo group had a baseline prostate volume of 155, which decreased to 85 at Year 4. The Finasteride group had a baseline prostate volume of 157, which decreased to 102 at Year 4.*

Figure 5 Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group - finasteride fig4

Figure 5 Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group - finasteride fig4

chemical structure - finasteride str

chemical structure - finasteride str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.